A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Status:	Completed
Conditions:	Arthritis, Rheumatoid Arthritis
Therapuetic Areas:	Rheumatology
Healthy:	No
Age Range:	18 - Any
Updated:	10/2/2013
Start Date:	March 2012
End Date:	May 2014
Contact:	Pfizer CT.gov Call Center
Phone:	1-800-718-1021

A Randomized, Double-Blind, Study Comparing The Pharmacokinetics And Pharmacodynamics, And Assessing The Safety Of PF-05280586 And Rituximab In Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate Who Have Had An Inadequate Response To One Or More TNF Antagonist Therapies

In this study, patients with moderate to severe rheumatoid arthritis who are being treated
with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan
(Rituximab) or MabThera (Rituximab). During the course of the study, the effects of the
drugs will be assessed by sampling the levels of drug in the blood, blood cell counts, and
by comparing these levels among the different treatments. Safety, tolerability and
immunologic response also will be evaluated throughout.

Inclusion Criteria:

- Confirmed diagnosis of rheumatoid arthritis

- Meets Class I, II or III of the ACR 1991 Revised Criteria

- RA seropositivity

- Stable dose of methotrexate

- Inadequate response to TNF inhibitors

Exclusion Criteria:

- Any prior treatment with lymphocyte depleting therapies

- History of active TB infection

- Known or screen test positive for specific viruses or indicators of viral infection

We found this trial at

sites

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Study Comparing The Pharmacokinetics And Pharmacodynamics, And Assessing The Safety Of PF-05280586 And Rituximab In Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate Who Have Had An Inadequate Response To One Or More TNF Antagonist Therapies

Select your condition

Common Conditions

All Conditions